Scientists identify molecule behind fat deposition and insulin release

Scientists at the Karolinska Institute in Sweden have identified a molecule which plays a key role in both the regulation of body fat and the release of insulin from the pancreas. Two papers presenting the results are published online by the journal the Proceedings of the National Academy of Sciences (PNAS). Both studies involve a receptor molecule called ALK7. ALK7 is found in several organs involved in regulating the metabolism, including the pancreas, adipose tissue, the gut and the brain. However, the physiological functions of this molecule are not well known.

In the first study, a team led by Carlos Ibáñez studied mice in which the gene responsible for producing ALK7 had been switched off. They found that these mice developed abnormally high levels of insulin in the blood. Over time, this led to a reduction in the body's sensitivity to insulin, impaired glucose tolerance and a condition called liver steatosis, in which the liver accumulates large amounts of fat. v In the second study, the researchers investigated the links between ALK7 and a growth factor called GDF3. The research revealed that when fed a high fat diet, mice lacking ALK7 accumulated less fat and gained less weight than normal mice, even though they ate the same amount of food. The scientists also discovered that GDF3 can send signals via the ALK7 receptor, and mice lacking GDF3 reacted to a high fat diet in the same way as mice lacking ALK7.

"These results show that lack of ALK7 or GDF3 improves energy balance in the body under regimes of high caloric intake," explained Professor Ibáñez, who also led the second study.

The researchers' findings have implications for the development of new treatments for both diabetes and obesity.

"We have shown in animal studies that removing the ALK7 receptor improves insulin release by beta cells in the pancreas, and at the same time decreases fat deposition in the situations of high caloric intake," concluded Professor Ibáñez. "The well known connections between diabetes and obesity make our combined findings quite exciting."

The work was funded in part by a Marie Curie grant from the EU.

For more information, please visit:
http://www.ki.se http://www.pnas.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...